Ocugen, Inc. OCGN
We take great care to ensure that the data presented and summarized in this overview for Ocugen, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OCGN
View all-
Black Rock Inc. New York, NY17.9MShares$21.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.2MShares$18.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.16MShares$4.95 Million0.0% of portfolio
-
Gmt Capital Corp Atlanta, GA4.15MShares$4.94 Million0.31% of portfolio
-
Geode Capital Management, LLC Boston, MA3.68MShares$4.38 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.57MShares$1.87 Million0.0% of portfolio
-
State Street Corp Boston, MA1.36MShares$1.61 Million0.0% of portfolio
-
Rinkey Investments San Diego, CA1.11MShares$1.32 Million0.49% of portfolio
-
Gsa Capital Partners LLP London, X01.04MShares$1.24 Million0.14% of portfolio
-
Ubs Group Ag1.02MShares$1.22 Million0.0% of portfolio
Latest Institutional Activity in OCGN
Top Purchases
Top Sells
About OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Insider Transactions at OCGN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 03
2025
|
Shankar Musunuri Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
177,146
-8.81%
|
$0
$0.89 P/Share
|
|
Jan 03
2025
|
Arun Upadhyay Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,633
-11.97%
|
$0
$0.89 P/Share
|
|
Nov 26
2024
|
Prabhavathi Fernandes Director |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$0
$0.91 P/Share
|
|
Nov 22
2024
|
Kirsten Castillo Director |
BUY
Open market or private purchase
|
Direct |
25,000
+25.0%
|
$0
$0.91 P/Share
|
|
Sep 16
2024
|
Arun Upadhyay Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
842
-0.24%
|
$842
$1.17 P/Share
|
|
Jun 17
2024
|
Arun Upadhyay Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
917
-0.26%
|
$917
$1.42 P/Share
|
|
Jan 03
2024
|
Arun Upadhyay Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,633
-10.64%
|
$0
$0.65 P/Share
|
|
Jan 03
2024
|
Shankar Musunuri Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
180,204
-8.23%
|
$0
$0.65 P/Share
|
|
Sep 16
2023
|
Arun Upadhyay Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
842
-0.21%
|
$0
$0.41 P/Share
|
|
Jun 16
2023
|
Arun Upadhyay Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
917
-0.23%
|
$0
$0.51 P/Share
|
|
Jun 14
2023
|
Junge Zhang Director |
BUY
Open market or private purchase
|
Indirect |
200,278
+15.68%
|
$0
$0.5 P/Share
|
|
Feb 16
2023
|
Shankar Musunuri Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-4.37%
|
$100,000
$1.08 P/Share
|
|
Feb 16
2023
|
Shankar Musunuri Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+4.18%
|
$0
$0.33 P/Share
|
|
Jan 17
2023
|
Shankar Musunuri Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-4.3%
|
$100,000
$1.28 P/Share
|
|
Jan 17
2023
|
Shankar Musunuri Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+4.12%
|
$0
$0.51 P/Share
|
|
Jan 03
2023
|
Shankar Musunuri Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,877
-1.7%
|
$37,877
$1.25 P/Share
|
|
Jan 03
2023
|
Jessica Crespo CAO/SVP, Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
1,913
-1.17%
|
$1,913
$1.25 P/Share
|
|
Jan 03
2023
|
Arun Upadhyay Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,102
-1.78%
|
$7,102
$1.25 P/Share
|
|
Jan 03
2023
|
Arun Upadhyay Officer |
BUY
Grant, award, or other acquisition
|
Direct |
315,924
+44.12%
|
-
|
|
Jan 03
2023
|
Shankar Musunuri Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,475,410
+39.84%
|
-
|
Last 12 Months Summary
| Payment of exercise price or tax liability | 219K shares |
|---|